Company news
Alto Neuroscience, Inc. news in 2025
Alto Neuroscience, Inc.'s news releases, calls and decks from 2025, newest first.
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
December 3, 2025
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 12, 2025
Alto Neuroscience to Participate in Upcoming Investor Conferences
October 28, 2025
Alto Neuroscience Announces $50 Million Private Placement Financing
October 20, 2025
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
October 20, 2025
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
October 3, 2025
Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
September 9, 2025
Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 13, 2025
Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
August 13, 2025
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
June 30, 2025
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
June 26, 2025
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
June 3, 2025
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder
May 29, 2025
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 14, 2025
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach
April 28, 2025
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day
April 22, 2025
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights
March 20, 2025
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
February 19, 2025
Decks in 2025
- TD Cowen 45th Annual Health Care Conference (March 2025)
Conference · 17 slides · Mar 4, 2025